登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式(希尔记法):
C19H19FN4O3
化学文摘社编号:
分子量:
370.38
UNSPSC Code:
12352200
NACRES:
NA.25
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
Fc1c2c([nH]c(c2)C)ccc1Oc3ncn[n]4c3c(c(c4)OC[C@H](O)C)C
InChI
1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
InChI key
WCWUXEGQKLTGDX-LLVKDONJSA-N
Biochem/physiol Actions
Brivanib (BMS-540215) is an orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor (VEGFR-1/2/3 IC50 = 380/25/10 nM; FGFR-1/2/3 IC50 = 148/125/68 nM). Brivanib inhibits VEGF-stimulated and basic FGF-stimulated proliferation in endothelial cultures (IC50 = 40 & 276 nM, respectively) and displays antitumor efficacy in vivo (30-90 mg/kg via daily p.o. in mice with H3396 xenografts).
Orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor with antitumor efficacy in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable